isatin beta-thiosemicarbazone profile

isatin beta-thiosemicarbazone: isatizon believed to be Russian synonym [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	690109
CHEMBL ID	240095
CHEMBL ID	333137
CHEMBL ID	1495416
SCHEMBL ID	98437
SCHEMBL ID	10084821
SCHEMBL ID	23483885
MeSH ID	M0061438

Synonym
HMS1578G07
isatin, 3-thiosemicarbazone
smr000184416
1h-indole-2,3-dione 3-thiosemicarbazone
MLS000595029 ,
CBDIVE_001125
isatin beta.-thiosemicarbazone
2,3-indoledione 3-(thiosemicarbazone)
hydrazinecarbothioamide, 2-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-
[(z)-(2-oxoindolin-3-ylidene)amino]thiourea
ibt
isatin 3-thiosemicarbazone
nsc 721
indole-2, 3-(thiosemicarbazone)
nsc721
nsc-721
gs 1752
isatin .beta.-thiosemicarbazone
487-16-1
isatin thiosemicarbazone
isatin-.beta.-thiosemicarbazone
2,3-indoledione 3-thiosemicarbazone
STK008099
(2z)-2-(2-oxo-1,2-dihydro-3h-indol-3-ylidene)hydrazinecarbothioamide
CHEMBL240095
bdbm50133615
(3z)-1h-indole-2,3-dione 3-thiosemicarbazone
AKOS000484002
isatin-3-thiosemicarbazone
CHEMBL333137 ,
[(2-oxoindol-3-yl)amino]thiourea
AKOS003627931
NCGC00245548-01
STL115046
(2e)-2-(2-hydroxy-3h-indol-3-ylidene)hydrazinecarbothioamide
HMS2512O10
ai3-51987
indole-2,3-dione, 3-(thiosemicarbazone)
einecs 207-650-6
isatin beta-thiosemicarbazone
(1,2-dihydro-2-oxo-3h-indol-3-al) thiosemicarbazone
isatin-beta-thiosemicarbazone
isatizon
hydrazinecarbothiamide, 2-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-
2-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)hydrazinecarbothioamide
AE-641/01080004
F1577-0011
27830-79-1
(z)-2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide
FT-0609745
11R-1254
{[(3z)-2-oxo-2,3-dihydro-1h-indol-3-ylidene]amino}thiourea
2-(2-oxo-1,2-dihydro-3h-indol-3-yliden)-1-hydrazinecarbothioamide
AKOS015855829
CHEMBL1495416
AKOS025310054
AB01209736-01
SCHEMBL98437
cid_5354107
1-[(2-oxidanylideneindol-3-yl)amino]thiourea
[(2-ketoindol-3-yl)amino]thiourea
bdbm78648
[(2-oxo-3-indolyl)amino]thiourea
J-502585
DTXSID5060067
SCHEMBL10084821
SLEMRAMJSGBARH-UHFFFAOYSA-N
3h-indole, 3-[2-(aminocarbonothioyl)hydrazono]-1,2-dihydro-2-oxo-
mfcd00043581
CCG-245002
2-(2-oxo-1,2-dihydro-3h-indol-3-yliden)-1-hydrazinecarbothioamide, aldrichcpr
zinc bis{n'-[(3z)-2-oxo-1,2-dihydro-3h-indol-3-ylidene]hydrazonothiocarbamate}
isatin-3-isothiosemicarbazone
2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide
(e)-2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide
(2-hydroxy-1h-indol-3-yl)iminothiourea
3-isatin thiosemicarbazone
SCHEMBL23483885
hydrazinecarbothioamide, 2-(1,2-dihydro-2-oxo-3h-indol-3-ylidene)-,(2z)-
A918224
(z)-2-(2-oxoindolin-3-ylidene)hydrazine-1-carbothioamide
CS-0336068
PD178050
PD178051

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	0.7079	0.0447	17.8581	100.0000	AID485294
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	10.0000	0.6310	35.7641	100.0000	AID504339
Chain A, Cruzipain	Trypanosoma cruzi	Potency	14.2191	0.0020	14.6779	39.8107	AID1476; AID1478
WRN	Homo sapiens (human)	Potency	10.0000	0.1683	31.2583	100.0000	AID651768
phosphopantetheinyl transferase	Bacillus subtilis	Potency	50.1187	0.1413	37.9142	100.0000	AID1490
Microtubule-associated protein tau	Homo sapiens (human)	Potency	12.5893	0.1800	13.5574	39.8107	AID1460
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	12.5893	0.7079	12.1943	39.8107	AID720542
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	35.4813	0.0112	12.4002	100.0000	AID1030
67.9K protein	Vaccinia virus	Potency	11.2947	0.0001	8.4406	100.0000	AID720579; AID720580
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	89.1251	0.0355	20.9770	89.1251	AID504332
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	19.9526	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	29.0929	0.0046	11.3741	33.4983	AID624296
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0041	9.9625	28.1838	AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ubiquitin-conjugating enzyme E2 N	Homo sapiens (human)	IC50 (µMol)	20.0000	0.8730	10.7219	78.4000	AID493155
Cruzipain	Trypanosoma cruzi	IC50 (µMol)	5.7500	0.0002	2.0450	8.0000	AID200223; AID213673
Cysteine proteinase falcipain 2a	Plasmodium falciparum (malaria parasite P. falciparum)	IC50 (µMol)	38.8000	0.0058	0.4403	5.0000	AID72520
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID350248	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID458587	Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach.
AID72520	Inhibitory activity against Falcipain-2	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain.
AID458586	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach.
AID350249	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID309307	Cytotoxicity against human CEM cells	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
AID309306	Cytotoxicity against human Molt 4/C8 cells	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
AID213673	Inhibitory activity against the Trypanosoma cruzi cysteine protease cruzain	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain.
AID244634	Ratio of Effective concentration to inhibit cowpox virus plaque formation to that of half maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.
AID246355	Effective concentration required to inhibit cowpox virus plaque formation in human foreskin fibroblast (HFF) cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.
AID309308	Cytotoxicity against mouse L1210 cells	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
AID628718	Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.
AID628717	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.
AID200223	Inhibitory activity against Trypanosoma brucei rhodesiense cysteine protease rhodesain	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain.
AID458588	Cytotoxicity against human MCF10A cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach.
AID245952	Half-maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.
AID244635	Ratio of Effective concentration to inhibit vaccinia virus plaque formation to that of half maximal cytotoxic concentration in human foreskin fibroblast (HFF) cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.
AID246367	Effective concentration required to inhibit vaccinia virus plaque formation in human foreskin fibroblast (HFF) cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.
AID458585	Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach.
AID757402	Inhibition of Trypanosoma brucei rhodesain	2013	Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14	Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID1368767	Inhibition of human GSK-3beta at 10 uM using YRRAAVPPSPSLSRHSSPHQS(p) EDEEE substrate peptide and [gamma-33P-ATP] incubated for 40 mins by scintillation counting method	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Discovery of new GSK-3β inhibitors through structure-based virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (35.71)	18.7374
1990's	4 (9.52)	18.2507
2000's	9 (21.43)	29.6817
2010's	13 (30.95)	24.3611
2020's	1 (2.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.22%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	44 (97.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
creatine [no description available]	1.94	1	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
glycine [no description available]	1.94	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	2.02	1	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	1.94	1	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	1.94	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.05	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	1.94	1	carboxamidine; guanidines; one-carbon compound
hydroxyurea [no description available]	1.96	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.08	1	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	1.98	1	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	1.94	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	2.02	1	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	1.94	1	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	1.94	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
5-bromoisatin [no description available]	2.01	1	indoles	anticoronaviral agent
isatin tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;	4.71	30	indoledione	EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.	1.94	1	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
5-methylisatin 5-methylisatin: structure in first source	2.01	1
n-methylisatin N-methylisatin: structure given in first source	2.36	2
staurosporine [no description available]	2.49	2	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.02	1	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
5-Chloro-1H-indole-2,3-dione [no description available]	2.01	1	indoles	anticoronaviral agent
5-iodoisatin 5-iodoisatin: structure in first source	2.01	1	indoles	anticoronaviral agent
2'-5'-oligoadenylate trimer 2',5'-oligoadenylate: inhibits protein synthesis in cell-free systems	2.38	2
benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone: inhibits cathepsins B and L	2.08	1	carboxylic ester; diazo compound; L-phenylalanine derivative; secondary carboxamide	cathepsin L (EC 3.4.22.15) inhibitor
5-Fluoroisatin [no description available]	2.01	1	indoles	anticoronaviral agent
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.17	1
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	1.98	1	actinomycin	mutagen
methisazone Methisazone: An antiviral agent effective against pox viruses.	2.37	2
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	1.94	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore
nsc73306 [no description available]	2.46	2
5-Nitroisatin [no description available]	2.01	1	indoles	anticoronaviral agent
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.17	1	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.08	1
su 11248 [no description available]	2.05	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone: structure	2.05	1
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.05	1
3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source	2.05	1
k11002 [no description available]	2.08	1
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.17	1	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sarkosyl sarkosyl: RN given is for sarkosyl L, the parent cpd; structure	2.02	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	1.96	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.03	1
Breast Cancer [description not available]	2.05	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
African Sleeping Sickness [description not available]	2.08	1
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	2.08	1
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	2.86	4
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.11	1
Amelia [description not available]	1.93	1
Viral Diseases [description not available]	2.34	2
Virus Diseases A general term for diseases caused by viruses.	2.34	2
Alastrim [description not available]	1.93	1
Smallpox An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)	1.93	1
Hypogammaglobulinemia [description not available]	1.93	1
Agammaglobulinemia An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.	1.93	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	7.02	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	1.95	1
Experimental Leukemia [description not available]	1.95	1
Chromosome Deletion Actual loss of portion of a chromosome.	1.97	1

isatin beta-thiosemicarbazone

Description

Cross-References

Synonyms (84)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Bioassays (36)

Research

Studies (42)

Market Indicators

Research Demand Index: 10.85

Study Types

isatin beta-thiosemicarbazone

Description

Cross-References

Synonyms (84)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Bioassays (36)

Research

Studies (42)

Market Indicators

Research Demand Index: 10.85

Study Types

Related Drugs (42)

Related Conditions (22)